Me: At conference eating a sandwich. Keto guru Doc: “You know that bread will kill you”. Me: “My grandfather lived to 104 years old”. Keto guru Doc: “By eating bread”? Me: “No, by minding his own business”. – at Toronto, Ontario

The GLP-1 receptor agonist semaglutide (Ozempic®/Wegovy®) -soon to be available at 7.2 mg once weekly- has been shown to reduce the incidence of cardiovascular death, non-fatal heart attacks, and non-fatal strokes in people living with established heart disease and overweight or obesity. So… cardiologists will now be prescribing GLP-1 agonists to their patients more frequently. If you are someone prescribing a GLP-1 receptor agonist or personally starting one, you’ll find this podcast extremely relevant. I was recently invited by @Dr. Grace Chua and the @Canadian Cardiovascular Society to discuss exactly this on the Cardio Connector Podcast episode “Sustaining Success: Real-World Approaches to Obesity Management.” In the episode, I share three key principles every cardiologist should integrate when prescribing these medications: 1️⃣ Addressing internalized weight bias
2️⃣ Discussing appetite dysregulation
3️⃣ Setting realistic weight loss expectations Integrating these principles is: 
🔹 Straightforward
✅ Simple
⏱️ Not time-consuming
⚡ Yet critical I suggest that doing so will meaningfully improve: 
✅ Medication adherence
❤️ Clinical outcomes 🎧 Listen to the full episode here: ccs.simplecast.com/episodes/… What challenges or successes are you seeing when discussing GLP-1 therapies with your patients (or in your own experience)? I’d love to hear your thoughts in the comments 👇 #Cardiology #GLP1 #Semaglutide #Ozempic #Wegovy #ObesityMedicine #PatientAdherence #CanadianCardiovascularSociety #HeartHealth

Standing room only in Malaga Spain at #ECO2025 as Dr. Horn presents the landmark Surmount-5 trial data published today in NEJM. nejm.org/doi/full/10.1056/NE…

Which obesity medication will be the next blockbuster? Please distribute. Opinion snapshot May 2024.

I predict that STRESS and SLEEP DEBT will prove much less impactful on obesity in the era of 2nd and next generation AOMs. Their effects will be described as relatively more pronounced in “the olden days” 😀 @KevinH_PhD & @sguyenet you would find this interesting, Anecdotally, patients on 2nd gen AOMs only start re-endorsing “stress eating” when they are out of the shaded part. Theoretically confounding stress with the neurological increased appetite response that follows weight loss.

My friend, colleague and mentor @DrSharma is about to succeed in yet another field, the music industry! Give a good listen to his debut release! Bravo Arya! listen.music-hub.com/oaEcTe – at Toronto, Ontario

Congratulations to the entire staff at MWM. Real world data Effective, expert and ethical treatment of obesity. Significant metabolic and psychological outcomes. Behavioural therapy +/- medication. A real life incarnation of the celebrated CDN guidelines. @meghapoddar – at Calgary, Alberta

Wow I just sat through the Calibre ( I teach Calibre this Friday) training conducted by my colleagues @seanwharton @DrSuePedersen @SanjSockalingam and Michael Vallis in Banff. Amazing teachers, researchers and clinicians! cpd.obesitycanada.ca/calibre…

Thanks @KurtBlack94 for ur excellent journalism and interview regarding Obesity. But… Please ask the producers to consider eliminating the stigmatizing video contained in the video piece below presenting headless ppl with donuts suggesting gluttony ??? youtu.be/DZ88FX2Jp0I?si=z2dU…

Really? Take a GLP-1 RA and then stop it at 18 months and all the great new habits plus food is medicine stuff and you will maintain weight loss. Pure fantasy. Denies biology. When meds finally cost less we can end these eat less move more platitudes. jamanetwork.com/journals/jam… – at Toronto, Ontario

Ditto😂 – at Dorval, Québec

Thanks @healthpsycleeds this is helpful. Stress affects obesity by a) increase the amplitude of appetite while at the same time b) diminishing self regulation capacity. This sys review & meta-analysis says Mindfulness-meditation interventions for the win pubmed.ncbi.nlm.nih.gov/3787…. – at Boston, MA

Hi @skathire I know you are busy with important lipids work 😀 but do you know of any progress with the exciting prospect of polygenic risk scores in obesity? Can power be ⬆️ with the availability larger databases? I’ll also check with Lee Kaplan… cell.com/cell/pdf/S0092-8674… – at Boston, MA

Ted @ConscienHealth, I had to check the date! Usually you reserve these for April 1st 😂 conscienhealth.org/2024/03/i… – at Boston, MA

Did you know that with GLP-1 RAs (for example Semaglutide) there are likely weight loss independent factors that contribute cardioprotection? Hmmm what may they be? Join us in one of the most beautiful places on earth to learn more😀 @ObesityCan site.pheedloop.com/event/sci… – at Toronto, Ontario

Great piece @IanPatton55 🙌 – at Toronto, Ontario